Oncology

Publications

Abu-Arja, MH; Rajabi, Z; Mcglynn, MC; Zobeck, M; Ghebrelul, RT; Zaghloul, MS; Elhemaly, A; Bertrand, K; Gajjar, A; Ronsley, R; Finlay, JL; Dhall, G; Nagabushan, S; Abdelbaki, MS. High-dose chemotherapy and re-irradiation associated with improved overall survival in patients with relapsed central nervous system (CNS) non-germinomatous germ cell tumors (NGGCT). Clinical Oncology. 2026; 57:104278.

Abu-Arja, MH; Rajabi, Z; Mcglynn, MC; Ghebrelul, RT; Zobeck, M; Harasis, S; Arora, J; Zaghloul, MS; Elhemaly, A; Bertrand, K; Finlay, JL; Dhall, G; Nagabushan, S; Abdelbaki, MS. Marrow-ablative chemotherapy and re-irradiation are associated with improved overall survival in patients with relapsed central nervous system nongerminomatous germ cell tumors. Journal of Neuro-Oncology. 2026; 177(3).

Ahmed, N; Ali, A; Kim, S; Oloyede, T; Bye, M; Gowda, L; Kamble, RT; Mirza, A-S; Nadiminti, KV; Pophali, PA; Pasquini, MC; Ahmed, S; Ganguly, S; Moskop, A. Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma. Transplantation and Cellular Therapy. 2026.

Appell, LE; Baggott, C; Nguyen, K; Prabhu, S; Pacenta, H; John, S; Fabrizio, VA; Phillips, CL; Rossoff, J; Talano, J-A; Mackall, CL; Laetsch, TW; Mcnerney, K; Schultz, LM. Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel. Blood advances. 2026; 10(1):106-110.

Armstrong, AE; Gross, AM; Klesse, LJ; Rhodes, SD; Ahlawat, S; Staedtke, V; Molina, CA; Hirbe, AC. Neurofibromatosis type 1-plexiform neurofibromas: Integrating treatment across pediatric and adult populations. Neuro-Oncology. 2026; 28(4):847-863.

Avery, RA; Gross, AM; Cousineau-Krieger, C; Keenan, TDL; Mcmanus, T; Dallas, CJ; Hampton, C; Baldwin, A; Jin, F; Heisey, K; Bishop, RJ; Fisher, MJ; Widemann, BC; Magone, MT. Long-term Ocular Safety in Children Treated with Mitogen-Activated Protein Kinase Pathway Inhibitor Therapy. Ophthalmology (Rochester, Minn.). 2026; 133(2):291-294.

Bajgain, P; Feng, Y; Puebla, M; Tian, M; Hsu, K-S; Lee, J; Yu, G; Yang, L; Seaman, S; Hilton, MB; Khan, J; Nellan, A; Kaplan, RN; St Croix, B. Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy. Cell Reports Medicine. 2026; 7(5):102782.

Bansal, N; Khanna, N; Kapusta, L; Ryan, TD; Leger, KJ; Bender, JD; Miller, EK; Dos Santos, MVC; Mavinkurve-Groothuis, AM; Martinez, HR. Global variability in cardiovascular care of pediatric cancer patients and survivors: survey results from the International Cardio Oncology Society (ICOS) Cardio-Oncology. 2026.

Barron, T; Drexler, R; Mochizuki, A; Cantor, E; Shamardani, K; Woo, PJ; Soni, N; Tlais, D; Franson, A; Lyons, S; Partap, S; Kaila, K; Koschmann, C; Monje, M. Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma. Nature Medicine. 2026; 32(10):3792-3800.

Bender, JD; Pommert, L; Backus, LR; Bidwell, A; Blank, C; Breese, EH; Burns, KC; Lane, A; Lee, LH; Mizukawa, B; Ryan, TD; Young, J; Absalon, M; Perentesis, JP. CPX-351 in High-Risk Relapsed Pediatric Acute Leukemia: Real-World Phase 1 Data Establishing the FDA-Approved Dose. Pediatric Blood and Cancer. 2026; 73(6):e70268.

Bender, JLG; Pressey, JG; Wagner, LM; Kim, A; Shah, AT; Federico, SM; Morgenstern, DA; Hoogstra, DJ; Crane, J; Bhatt, K; Cai, G; Miao, X; Ma, J; Laetsch, TW. Safety and pharmacokinetics (PK) of lurbinectedin (lurbi) in pediatric patients (pts) with relapsed/refractory (R/R) solid tumors and preliminary antitumor activity in pediatric and young adult pts with R/R Ewing sarcoma (EwS): Results from a phase 1 study. Journal of Clinical Oncology. 2026; 44(16_suppl):11518-11518.

Benoit, S; Rose, J; Jenkins, K; Lindquist, D; Webster, A; Perentesis, J; Mascia, A. EP074 / #800 SINGLE-CELL EVIDENCE OF LATE KIDNEY INJURY AFTER PROTON BEAM THERAPY DESPITE PRESERVED RENAL FUNCTION. International Journal of Particle Therapy. 2026; 21:101399.

Biswas, K; Ghosh, S; Khincha, PP; Sundby, T; Singh, A; Ault, G; Henderson, M; Gross, AM; Donoghue, M; Savage, SA; Widemann, BC; Shoemaker, RH; Mohammed, A. Rare cancers research: Current state of knowledge and emerging opportunities for prevention and interception. Journal of the National Cancer Institute. 2026.

Brammer, CN; Lee, T; Bahakel, H; Kim, H; Paulsen, GC; Miller-Handley, H; Pommert, L; Danziger-Isakov, LA; Otto, WR. P-522. Epidemiology of respiratory viral infections in pediatric acute leukemia patients. Open Forum Infectious Diseases. 2026; 13(Supplement_1):ofaf695.737.

Chansky, P; Rubinstein, J; Grimley, M; Davies, SM; Blyth, E; Gottlieb, D; Pulsipher, MA; Bollard, C; Keller, MD; Li, W. Boosting the Predictive Power of Virus-Specific T-Cell Clinical Trials via Generative Models. Computational and Structural Biotechnology Journal. 2026; 35(1):0208.

Chohan, KL; Feng, L; Cochran, H; Rosenberg, M; Isenalumhe, L; Yilmaz, E; Kim, S-H; Tiger, YK; Torka, P; Flanagan, H; Hamadani, M; Diefenbach, C; Bartlett, N; Ahmed, S. Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma. British Journal of Haematology. 2026.

Colace, SI; Pommert, L; Leger, KJ; Rushing, T; Crews, KR; Annesley, C; Bernhardt, MB; Ramsey, LB; Kaiser, N; Bhojwani, D; Gaynon, PS; Sachdeva, R; Schafer, ES; Sabnis, HS. Cardio-protection and monitoring for early phase clinical trials: Recommendations from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Journal of the National Cancer Institute. 2026.

Crisler, KM; Klages, KL; Mara, CA; Norris, RE; Ketterl, TG; Perentesis, JP; Mcgrady, ME. Social Support and Barriers to Medication Adherence Among Adolescents and Young Adults With Cancer. Pediatric Blood and Cancer. 2026; e70723.

Curlee, MS; Siegel, A; Little, P; Toledo-Tamula, MA; Martin, S; Gross, AM; Yohe, ME; Aryavand, M; Frone, MN; Ney, GM; Stewart, DR; Wolters, PL. Wide Ranging Neurobehavioral Phenotype in Individuals With Costello Syndrome. American Journal of Medical Genetics, Part A. 2026; 200(5):1138-1144.

Daugherty, EC; Zhang, Y; Xiao, Z; Backus, L; Mcdonald, JM; Stockman, B; Woo, J; Mccann, C; Russell, K; Sharma, R; Simone, CB; Breneman, J; Perentesis, JP; Mascia, AE. FAST-02: Results from the second in-human prospective evaluation of single-fraction proton FLASH for symptomatic thoracic bone metastases. Radiotherapy and Oncology. 2026; 222:111671.

Davies, SM; Blyth, E; Bollard, CM; Craddock, J; Dahi, PB; Gottlieb, D; Grimley, MB; Keller, MD; Khoury, R; Olson, AL; Spivey, SM; Vasileiou, S; Prockop, SE; Heslop, HE. Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT. Transplantation and Cellular Therapy. 2026; 32(9):1051.e1-1051.e10.

Deng, B; Zhong, X; Xin, D; Huang, X; Soni, UK; Ma, W; Cai, M; Liang, P-Y; Bai, J; Qin, Q; Koschmann, C; Cancelas, JA; Zheng, Y; Lu, QR. A CAR-T Tonic Signaling Code Predicts Anti-Tumor Efficacy in Diffuse Midline Glioma. Neuro-Oncology. 2026.

Dong, EE; Schiff, D; Rossoff, J; Hoover, A; Pacenta, H; Stieglitz, E; Skiles, J; Phillips, CL; Guest, E; Bender, JD; Schultz, L. Venetoclax as Salvage Treatment for Relapsed/Refractory B-ALL Post-CAR-T Therapy. Pediatric Blood and Cancer. 2026.

Drucker, M; Lane, A; Aftandilian, C; Davis, KL; Rheingold, SR; Ball, D; Faulk, KE; O'brien, MM; Stokke, J; Bhojwani, D; Kotecha, RS; Rubinstein, JD. A real-world multi-institution experience of standard versus alternative dosing regimens of inotuzumab ozogamicin for relapsed/refractory paediatric B-cell acute lymphoblastic leukaemia. British Journal of Haematology. 2026.

Faulk, KE; Kairalla, JA; Hibbitts, E; Long-Boyle, J; Devidas, M; August, A; Gore, L; Raetz, E; Hunger, SP; Loh, ML; Teachey, DT; Brown, P; Breese, EH; Kotecha, RS; Guest, E. Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1. Blood advances. 2026; 10(1):70-74.

Ferreira, L; Sorrell, M; Raskin, SI; Kim, SY. DNMT3A R882C variant in a patient with a presumed pineal gland tumor, highlighting potential tumor susceptibility in Tatton-Brown-Rahman syndrome. Cancer Genetics. 2026; 302-303:162-165.

Fobare, S; Sharpe, C; Quinn, K; Bryant, K; Miles, LA; Bowman, RL; Cheney, C; Furby, C; Long, M; Fyock, K; Perentesis, JP; Eisfeld, A-K; Hertlein, E; Byrd, JC. Characterization of the clonal hierarchy and immunophenotype of PTPN11 mutations in acute myeloid leukemia. JCI Insight. 2026; 11(4).

Galletta, TJ; Rubinstein, JD; Dandoy, CE; Khoury, R; Faulhaber, A; Phillips, CL; Krupski, C. Emapalumab for Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CD19-Directed CAR-T in Two Patients With B-ALL: Clinical and Biomarker Correlates. Pediatric Blood and Cancer. 2026; 73(8):e70406.

Galletta, TJ; Rubinstein, JD; Krupski, C; Dandoy, CE; Khoury, R; Faulhaber, A; Davies, SM; Phillips, CL. Biomarker Elevations Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome after CD19-Directed CAR-T Therapy in Children and Young Adults with Acute B-Lymphoblastic Leukemia. Transplantation and Cellular Therapy. 2026; 32(2):s177.

Gardner, KL; Lange, TE; Perna, MK; Wells, SI; Williams, MT; Vorhees, CV; Cox, M; Solomon, MB; Privette Vinnedge, LM. DEK Loss Induces Task-specific Deficits in Learning and Memory and Reprograms the Hippocampal Transcriptome in Mice. Molecular Neurobiology. 2026; 63(1).

Gilene, S; Miller, C; Cronk, JC; Graham, RT; Gross, AM; Hummel, TR; Kotch, C; Mochizuki, AY; Raskin, S; Pillay-Smiley, N; De Blank, P. MEK inhibitor-induced dropped head syndrome in pediatrics. Neuro-Oncology Pediatrics. 2026; 2(2):wuag024.

Gross, AM; Rhodes, SD; Dufek, A; Dombi, E; Baldwin, A; Shern, JF; Sundby, RT; Zhang, X; Pekmezci, M; Clapp, DW; Bornhorst, M; Kim, A; Fisher, MJ; Widemann, BC. Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series. Neuro-Oncology Advances. 2026; 8(1):vdag180.

Gruber, TA; Jeha, S; Deyell, RJ; Lewis, V; Chang, BH; Lowe, EJ; Frediani, J; Vezina, C; Michon, B; Richards, M; Athale, U; Stearns, D; Schiff, D; Gaynon, PS. Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study. The Lancet Haematology. 2026; 13(3):e144-e156.

Guerrettaz, R; Peterson, A; Allbee-Johnson, M; Ahn, KW; Rotz, SJ; Sharma, A; Im, A; Nuechterlein, B; Ahmed, S; Mehta, PA; Phillips, CL; Higgins, R; Broglie, L; Phelan, R. Outcomes of Allogeneic Stem Cell Transplantation In the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia Based on Transplant Center: A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. Transplantation and Cellular Therapy. 2026; 32(2):s112.

Haney, M; Pommert, L. Base-Edited Breakthrough: Universal CD7 Chimeric Antigen Receptor T Cells Rewriting the Playbook for Relapsed T-Cell Acute Lymphoblastic Leukemia. The Hematologist. 2026; 23(3).

Hansford, J; Valvi, S; Dodgshun, A; Manoharan, N; Moore, C; Hassall, T; De Luca, C; Dawes, L; Goldstein, R; Waddell, N; Olsen, K; Dube, C; Orozco, NM; Wainwright, B. ID #112 PAEDNEOVAX - Multicentre, investigator-initiated phase I/II study to assess safety and efficacy of personalised mRNA vaccine targetting tumour-associated neoantigens in children and young adults with high-risk brain tumours. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.021.

Hoeksema, P; Hayatghaibi, S; Sharp, SE; Li, Y; Anton, CG; Norris, RE; Trout, AT. Discrepancies between primary and secondary interpretations of pediatric nuclear medicine imaging examinations. Pediatric Radiology. 2026; 56(2):464-472.

Husami, A; Mochizuki, A; Guan, Q; Zhang, W; Nagaraj, CB; Fabelo, C; Phillips, C; Dawson, B; Kim, SY. Discordant neoplasms in monozygotic twins with a germline RECQL5 variant. Cancer Genetics. 2026; 306-307:232-236.

Ikegami, S; Pandey, V; Wang, X; Sridharan, A; Mccormack-Spivey, S; Lutzko, CM; Cancelas, JA; Heyenbruch, D; Leemhuis, T; Alquist, CR; Khoury, R; Rubinstein, JD; Davies, S; Grimley, M. LONG-TERM CRYOPRESERVATION PRESERVES THE BIOLOGICAL AND MECHANOBIOLOGICAL ACTIVITY OF THIRD-PARTY VIRUS-SPECIFIC T CELLS. Cytotherapy. 2026; 28(5):102608.

Ivey, N; Zhang, JF; Zack, A; Kakazu, A; Jandarov, R; Kaye, J; Smith, I; Na, J; Koscielski, M; Hagen, M; Wang, K; Plas, DR; Jennifer L, L; A, J. Predictive capacity of mismatch repair status in the use of immune checkpoint inhibitors for the treatment of aggressive pituitary tumors and pituitary carcinomas: An illustrative case report and literature review. Surgical Neurology International. 2026; 17:252.

Kazerooni, AF; Jiang, Z; Gandhi, D; Khalili, N; Liu, X; Tu, W; Ware, JB; Familiar, AM; Vunnava, B; Zapaishchykova, A; Resnick, AC; Nabavizadeh, A; Vossough, A; Linguraru, MG. Multi-Institutional Annotated Multiparametric MRI Dataset of Pediatric High-Grade Gliomas. Radiology: Artificial Intelligence. 2026; 8(3):e250902.

Kelleher, JA; Bernstein, JL; Crisler, KM; Herriott, JK; Klages, KL; Norris, RE; Strenk, ML; Bills, SE; Mcgrady, ME. Patient-Level Barriers and Facilitators to Inpatient Physical Therapy in Adolescents and Young Adults With a Hematological Malignancy: A Qualitative Study. Pediatric Blood and Cancer. 2026; 73(4):e70129.

Kim, J; Ney, G; Frone, MN; Haley, JS; Ramos, MLF; Mirshahi, UL; Astiazaran-Symonds, E; Shandrina, M; Urban, G; Rao, HS; Ding, Y; Carey, DJ; Gelb, BD; Stewart, DR. Cancer risk in adults with pathogenic germline variants in RAS/MAPK genes using genomic ascertainment. Genetics in Medicine. 2026; 28(6):102561.

Kim, A; Ballman, KV; Wolters, PL; Heise, RS; Shern, JF; Sundby, RT; Lindenberg, L; Lee, M-J; Rastogi, S; Sato, N; Gross, AM; Reinke, D; Cichowski, K; Widemann, BC. SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST). Clinical Cancer Research. 2026; 32(6):1068-1077.

Kirstein, A; Ionascu, D; Lamba, M; Lange, T; Ruffolo, B; Crail, K; Vicente-Muñoz, S; Mascia, A; Sertorio, M; Hinrichs, B; Wise-Draper, T; Perentesis, J; Zheng, Y; Wells, S. OP191 / #572 PROTON THERAPY ELICITS A UNIQUE TRANSCRIPTOMIC RESPONSE IN ORAL CANCER ORGANOIDS. International Journal of Particle Therapy. 2026; 21:101929.

Kirstein, A; Ionascu, D; Lamba, MAS; Ruffolo, BM; Crail, KJ; Mascia, AE; Sertorio, MG; Hinrichs, BH; Zender, C; Lehn, MA; Wise-Draper, TM; Perentesis, JP; Zheng, Y; Wells, SI. In vitro determination of patient-specific variation challenges the universal RBE gold standard for proton radiation therapy. Clinical and Translational Radiation Oncology. 2026; 56:101046.

Kittle, HD; Bergus, KC; Bricker, J; Fallat, M; Hertweck, SP; Hewitt, G; Lutz, C; Aldrink, JH; Bence, C; Breech, L; St Peter, SD; Asti, L; Deans, K; Minneci, PC. Use of Radiographic Features for Risk Stratification of Ovarian Masses in Children and Adolescents. Journal of Surgical Research. 2026; 326:507-517.

Klages, KL; Nelson, CI; Herriott, JK; Norris, RE; Mcgrady, ME; Kashikar-Zuck, S; Pai, ALH. Pain Experiences During Early Treatment for Pediatric Acute Lymphoblastic Leukemia: A Qualitative Study. Psycho-Oncology. 2026; 35(7):e70550.

Klages, KL; Herriott, JK; Breen, G; Norris, RE; Beal, SJ; Sorge, CE; Pai, ALH; Mcgrady, ME. Pain, Internalizing Symptoms, Posttraumatic Stress, and Alcohol Use Among Young Adult Survivors of Cancer. Pediatric Blood and Cancer. 2026; 73(4):e70154.

Knickel, HJ; Rompies, EJ; Krallman, KA; Pillay-Smiley, N; Salloum, R; Goldstein, SL. Acute kidney injury during treatment of pediatric brain tumors: a retrospective analysis of survivors. Pediatric Research. 2026.

Kotch, C; Perreault, S; Power, P; Adams, DJ; Aldape, K; Avery, RA; Bandopadhayay, P; Capper, D; De Blank, P; Entz-Werle, N; Zhu, Y; Fisher, MJ; Hargrave, D; Kilburn, LB. Tempered optimism: Advances in the precision medicine era for pediatric low-grade glioma. Neuro-Oncology. 2026; 28(9):2110-2122.

Kotch, C; De Blank, P; Romo, C; Bhatia, A; Azizi, A; Siegel, B; Bui, A; Klesse, L; Foreman, N; Perreault, S; Blakeley, J; Gutmann, D; Piotrowski, A; Fisher, M. ID #141 The Use of MEK Inhibitors for Neurofibromatosis Type 1-Associated High Grade Glioma and High-Grade Astrocytoma with Piloid Features in Children and Young Adults: A Real-World Cohort Analysis. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.032.

Kotch, C; De Blank, P; Fangusaro, J; Fisher, MJ. MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors. Neuro-Oncology Advances. 2026; 8(Suppl 2):ii14-ii24.

Kotch, C; Avery, RA; Franson, AT; Hargrave, D; Brossier, NM; Bornhorst, M; Rangnath, S; Nevel, KS; Robison, NJ; Liu, GT; Fisher, MJ; De Blank, P. Clinical safety and efficacy of bevacizumab in combination with mitogen-activated protein kinase kinase inhibitor therapy for glioma: a retrospective analysis. Neuro-Oncology Pediatrics. 2026; 2(1).

Kraft, IL; Akshintala, S; Gross, A; Dombi, E; Turkbey, B; Bednarova, S; Ward, JF; Yedururi, S; Merino, M; Pinto, PA; Widemann, BC; Shern, JF; Waguespack, SG; Glod, J. The Prostate is a Common Site of Disease in Patients with MEN2B and Medullary Thyroid Carcinoma. Endocrine-Related Cancer. 2026; 33(1).

Kundu, I; Toro, N; Mochizuki, A; Cronk, J; Langhnoja, J; Ayyagari, R; Reel, S; Arounleut, P; Esqueda, LT; Fuller, C; Viswanath, P; Heimberger, A; Horbinski, C; Phoenix, T. ID #1015 A murine model system for IDH-mutant 1p/19q-codeleted oligodendroglioma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.446.

Kundu, IG; Toro, N; Mochizuki, AY; Langhnoja, J; Ayyagari, RV; Cronk, JC; Reel, SM; Arounleut, P; Tron Esqueda, LE; Fuller, CE; Viswanath, P; Heimberger, AB; Horbinski, CM; Phoenix, TN. Murine modeling of IDH-mutant 1p/19q-codeleted oligodendroglioma reveals genotype specific phenotypes. Neuro-Oncology. 2026.

Lazow, M; Schieffer, K; Paulson, V; Thomas, D; Cole, B; Fuller, C; Salloum, R; Palmer, J; Carceller, F; Wright, K; Filbin, M; Hargrave, D; Jones, C; Fouladi, M. ID #1132 CONNECT TarGeT-A molecularly-guided phase 2 trial for children and young adults newly diagnosed with high-grade glioma (HGG), including diffuse intrinsic pontine glioma (DIPG): (1) Ribociclib and everolimus for HGG/DIPG with cell cycle and/or PI3K/mTOR pathway alterations, and (2) Ribociclib and temozolomide for diffuse hemispheric glioma (DHG), H3G34-mutant. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.514.

Lazow, M; Schieffer, K; Thomas, D; Paulson, V; Cole, B; Fuller, C; Valvi, S; Gottardo, N; Fisher, M; Plant, A; Mardis, E; Hargrave, D; Jones, C; Fouladi, M. ID #1122 Preliminary feasibility of an international, multidisciplinary central screening platform for the CONNECT TarGeT molecularly-guided phase 2 umbrella trial for children and young adults with newly-diagnosed high-grade glioma (HGG) including diffuse intrinsic pontine glioma (DIPG) Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.507.

Levine, AB; Bennett, J; Patil, P; Burns, I; Siddaway, R; Li, C; Haizel-Cobbina, J; Rana, M; Yuditskiy, R; Son, A; Rutka, JT; Dewan, MC; Tabori, U; Hawkins, CE. Integrated clinical and molecular landscape of disseminated pediatric low-grade glioma. Neuro-Oncology. 2026; 28(2):535-551.

Li, J; Merkel, E; Grier, D; Zimmermann, N; Hodjat, P; Sabharwal, S; Breese, EH; Lorsbach, RB. Maternal-Fetal Transmission of Diffuse Large B-Cell Lymphoma. Pediatric Blood and Cancer. 2026; 73(2):e32174.

Liberio, N; Allbee-Johnson, M; Ahn, KW; Moskop, A; Phelan, R; Shaw, BE; Page, KM; Schultz, KR; Phillips, CL; Mehta, PA; Kapoor, N; Doherty, EE; Chavan, RS; Broglie, L. Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant. Journal of Clinical Oncology. 2026; 44(11):1003-1015.

Lyons, KU; Miller, KR; Deb, A; Nicklawsky, A; Baggott, C; Nguyen, K; Prabhu, S; Pacenta, H; Phillips, CL; Rossoff, J; Curran, KJ; Verneris, MR; Schultz, LM; Fabrizio, VA. Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults. Blood advances. 2026; 10(20):7115-7124.

Margol, AS; Hoffman, LM; Ronsley, R; Tran, J; Malvar, J; Chi, Y-Y; Leary, S; Stevens, J; Faulk, KE; Salloum, R; Gilheeney, S; Szalontay, L; Reddy, AT; Dhall, G. A multi-institutional report of children with atypical teratoid rhabdoid tumor treated with intensive multimodal therapy. Neuro-Oncology Practice. 2026; 13(4):807-815.

Marshall, MK; Tolani, D; Bender, JD; Lamour, JM; Bansal, N. Heart transplantation in pediatric oncology patients. JHLT Open. 2026; 12:100514.

Mccormack-Spivey, S; Wilhelm, J; Ikegami, S; Hudda, Z; Khoury, R; Davies, SM; Grimley, M; Rubinstein, JD. Duration of Cryopreservation of Third-party Viral Specific T-cells (TP-VSTs) Does Not Influence Clinical Efficacy. Transplantation and Cellular Therapy. 2026.

Mccormack-Spivey, S; Wilhelm, J; Ikegami, S; Rubinstein, JD; Hudda, Z; Khoury, R; Davies, SM; Grimley, MS. Duration of Cryopreservation of Third-Party Viral Specific T-Cells (TP-VSTs) Does Not Influence Clinical Efficacy. Transplantation and Cellular Therapy. 2026; 32(2):s131.

Mcglynn, MC; Abu-Arja, MH; Zaghloul, MS; Bertrand, K; Gajjar, A; Alias, H; Cappellano, A; Graham, RT; Baglivo, SJ; Bhadri, V; Mueller, S; Dhall, G; Nagabushan, S; Abdelbaki, MS. Multi-institutional analysis of pediatric relapsed/progressive central nervous system germinomas. Clinical Oncology. 2026; 57:104266.

Mcgrady, ME; Ketterl, TG; Webster, RT; Burns, MMK; Bills, SE; Burke, M; Szulczewski, L; Brock, MY; Schwartz, LE; Herriott, JK; Hommel, KA; Pai, ALH; Mara, CA; Norris, RE. Feasibility Trial of a Tailored Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer. Pediatric Blood and Cancer. 2026; 73(1):e32127.

Mcnerney, KO; Kwon, S; Naik, S; Fabrizio, VA; Caraballo, GL; Sanchez-Pinto, LN; Talleur, A; Zeng, X; Baggott, C; Vatsayan, A; John, S; Laetsch, TW; Gardner, R; Schultz, LM. HLH-like syndromes associate with increased risk of death and CD19- relapse after CAR T in pediatric B-ALL. Blood advances. 2026; 10(19):6422-6434.

Mcnerney, KO; Kwon, S; Naik, S; Fabrizio, VA; Llaurador, G; Sanchez-Pinto, LN; Talleur, AC; Zeng, XL; Baggott, C; Vatsayan, A; Mackall, CL; Laetsch, TW; Gardner, RA; Schultz, L. Validation of a Pre-Infusion Prediction Model for IEC-HS in Children and Young Adults with B-Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy. 2026; 32(2):s580.

Merker, VL; Ahlawat, S; Avery, RA; Bradford, D; Gross, AM; Janusz, J; Lessing, AJ; Manth, L; Mcmanus, ML; Oberlander, B; Walsh, KS; Wolters, PL; Widemann, BC; Plotkin, SR. New Approaches to Clinical Trials for Rare Diseases: Decentralized Trial Design for Neurofibromatosis Type 1 and Schwannomatosis. Cancers. 2026; 18(15).

Michaiel, G; Evans, N; Raghuram, N; Nobre, L; Vanan, MI; Hassan, H; Felton, K; Cacciotti, C; Zelcer, S; Fleming, A; Dvir, R; Abdelbaki, M; Ramaswamy, V; Cheng, S. ID #890 Multi-institutional analysis of outcomes of pediatric patients with high-risk (HR) WNT-subtype medulloblastoma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.384.

Miller, C; Smiley, NP; Wied, H. ID #634 Case Series of the Use of Trihexyphenidyl for Tremors in Pediatric Brain Tumors. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.247.

Miller, C; Smiley, NP; Melchers, J; Omaley, M; Feist, S. ID #472 Burnout Among Advanced Practice Providers in a Pediatric Oncology Setting. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.168.

Miller, C; Camardo, H; Fohl, D; Davis, J; Hummel, T; Mochizuki, A; Smiley, NP; Graham, R; Raskin, S; Frankart, A; Pater, L; De Blank, P. ID #1002 Hematologic Toxicity during Proton Radiation: a Review of Weekly CBC Results at a Single Center. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.440.

Mishra, AK; Pommert, L. Small Patients, Big Questions: Contemporary Therapeutic Strategies in Infants With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia. The Hematologist. 2026; 23(4).

Nisarga, P; Rathore, B; Hodjat, P; Derinkuyu, BE; Graham, RT; Skoch, J; Leino, D; Gupta, K. Diagnostic pitfall: BCOR immunoreactivity in a molecularly confirmed astroblastoma, MN1-altered (HGNET-MN1). Clinical Neuropathology. 2026; 45(1):32-35.

Orduña, P; Cansanay, RD; Erker, C; Ratterman, E; Schlosser, MP; Ronsley, R; Cacciotti, C; Cheng, S; Hukin, J; Aguilera, D; Rutkowski, S; Lassaletta, A; Bouffet, E; Lafay-Cousin, L. Group 4 Medulloblastomas of Early Childhood Treated With High-Dose Chemotherapy- and Craniospinal Irradiation-Sparing Approach. Pediatric Blood and Cancer. 2026; 73(5):e70181.

Peters, EJ; Gardner, KL; Privette Vinnedge, LM. All hands on DEK: structural insights into a unique histone modifier and chromatin remodeler. Epigenetics and Chromatin. 2026; 19(1).

Pommert, L. One Size Doesn’t Fit All: International Consensus Recommendations for Pediatric Acute Myeloid Leukemia. The Hematologist. 2026; 23(5).

Pommert, L. First, Do No Transplant? Emerging Evidence for Watchful Waiting in Select Juvenile Myelomonocytic Leukemia Patients. The Hematologist. 2026; 23(2).

Pommert, L; Tasian, SK. No Data Zone Hope on Hold: Novel Drug Access Out of Reach for Children With Acute Myeloid Leukemia Despite Adult Successes. The Hematologist. 2026; 23(1).

Rangarajan, HG; Chellapandian, D; Atshan, R; Ahn, KW; Kumar, S; Knight, TE; Leung, W; Ganguly, S; Williams, KM; Shah, NN; Qayed, M; Sharma, A; Broglie, L; Satwani, P. Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults With Acute Myeloid Leukemia: A CIBMTR Report. Transplantation and Cellular Therapy. 2026; 32(5):580.e1-580.e18.

Raskin, S; Yang, C; Lin, T; Yearley, J; Blumenschein, W; Pillay-Smiley, N; Lenzen, A; Partap, S; Fangusaro, J; Gururangan, S; Onar-Thomas, A; Fouladi, M; Dunkel, I; Mitchell, DA; Hwang, EI. An analysis of PD1 pathway activity in malignant pediatric central nervous system tumors: a pediatric brain tumor consortium study, PBTC-N13. Neuro-Oncology Pediatrics. 2026; 2(2):wuag020.

Rawashdeh, M; Gilene, S; Choi, K; Shah, V; De Blank, P. 028 Prevalence of optic nerve hypoplasia in neurofibromatosis type 1. Journal of AAPOS. 2026; 30(4):104940.

Rawashdeh, M; Gilene, S; Hummel, T; Smiley, NP; Graham, R; Mochizuki, A; Raskin, S; Shah, V; De Blank, P. ID #476 Increased Prevalence of Optic Nerve Hypoplasia in Neurofibromatosis Type 1. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.170.

Reel, S; Roy, S; Leino, D; Gatts, J; Raskin, S. ID #18 CHD7-associated CHARGE Syndrome and a spinal schwannoma with a SH3PXD2A::HTRA1 fusion: A case report. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.001.

Reel, SM; Roy, S; Leino, D; Gatts, J; Raskin, S. The first described report of a patient with CHD7-associated CHARGE syndrome and a spinal schwannoma with a SH3PXD2A::HTRA1 fusion; a case report and review of literature. Neuro-Oncology Pediatrics. 2026; 2(2):wuag034.

Reel, SM; Raskin, S. Overview of the neurotrophic tyrosine receptor kinase signaling pathway and therapeutic applications to brain tumors. In: Handbook of Brain Tumor Chemotherapy Molecular Therapeutics and Immunotherapy. 2026:501-513.

Reel, SM; Raskin, S. Chapter 29 Overview of the neurotrophic tyrosine receptor kinase signaling pathway and therapeutic applications to brain tumors. In: Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy. Elsevier; 2026:501-513.

Reiff, S; Cronk, J; Graham, R; Hummel, T; Mochizuki, A; Smiley, NP; De Blank, P; Raskin, S. ID #1028 A Retrospective Review Characterizing the Toxicities, Outcomes, and Molecular Characteristics of Adolescent and Young Adult Patients with Medulloblastoma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.457.

Renfro, LA; Vallance, KL; Tfirn, IC; Evageliou, N; Benedetti, DJ; Shamberger, RC; Ehrlich, PF; Cost, NG; Aldrink, JH; Schechter, A; Fernandez, CV; Dome, JS; Geller, JI; Mullen, EA. Associations of Patient Age, Tumor Nephrectomy Weight, and Tumor Diameter With Event-free and Overall Survival in Stage I or II Favorable Histology Wilms Tumor: A Pooled Analysis of Children's Oncology Group Studies AREN0532 and AREN03B2. Annals of Surgery. 2026; 284(4):759-767.

Rutherford, TA; Gilene, S; Haacker, L; Sorger, J; Turpin, B; Jamshidi-Nezhad, R; Cooper, B; Kemp, J; Pressey, JG. Retrospective Case Series Highlighting the Real-World Experience of Nirogacestat Therapy in Young Adults With Desmoid Tumors. Pediatric Blood and Cancer. 2026; 73(9):e70517.

Sabnis, HS; Pauly, M; Schafer, ES; Norris, RE; Ginn, K; Yeung, T; Kumar, N; Senn, S; Cowan, H; Deryckere, D; Forlenza, CJ; Shukla, N. ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T-Cell Lymphoblastic Leukemia/Lymphoma. Pediatric Blood and Cancer. 2026; 73(11):e70662.

Sachs, CM; Gross, AM; Widemann, BC; Shern, JF; Sundby, RT. Abstract 2548: Circulating proteomic signatures for subtyping NF1 associated peripheral nerve sheath tumors. Cancer Research. 2026; 86(7_Supplement):2548-2548.

Salloum, R; Stewart, C; Schieffer, K; Balow, S; Leino, D; Lenzen, A; Waanders, A; Baxter, P; Lindsay, H; Poussaint, T; Onar-Thomas, A; O’Halloran, K; Fouladi, M; Dunkel, I. ID #854 Updated findings from a phase 1 study of savolitinib in recurrent, progressive, or refractory medulloblastoma (MB), high-grade glioma (HGG), diffuse intrinsic pontine glioma (DIPG), and central nervous system (CNS) tumors harboring MET aberrations: A Pediatric Brain Tumor Consortium Trial: PBTC-049. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.360.

Salloum, R; Purzner, T; Stewart, C; Wang, Y; Leino, D; Cottrell, C; Jamal, B; Abdullaev, Z; Poussaint, T; Li, G; Fangusaro, J; Fouladi, M; Onar, A; Dunkel, I. ID #651 A phase 1/2 and surgical Pediatric Brain Tumor Consortium (PBTC) study evaluating the casein kinase 2 (CK2) inhibitor CX-4945 (silmitasertib sodium) in children and adults with recurrent sonic hedgehog (SHH) medulloblastoma (MB): PBTC-053. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.260.

Sankaran, H; Dombi, E; Glassberg, B; Baldwin, A; Heisey, K; Dufek, A; Tibery, C; Best, AF; Chen, AP; Widemann, BC; Gross, AM. Risk of developing malignant peripheral nerve sheath tumors in patients with neurofibromatosis 1 receiving MEK inhibitor treatment for plexiform neurofibromas. Neuro-Oncology Advances. 2026; 8(1):vdag201.

Schuemann, J; Rothwell, B; Mascia, A; Fan, Y; Loo, BW; Yock, T; Liu, KX; Perentesis, J; Haas-Kogan, DA. The potential and risks of FLASH radiotherapy in pediatric patients. Neuro-Oncology Pediatrics. 2026; 2(1):wuaf014.

Segal, J; Cronk, J; Ball, B; Forbes, G; Jackett, K; Li, K; Osorno, AM; Montalvan, ESA; Browne, A; Lake, J; Kaplan, RN. Parallels in Canonical Developmental Signaling Pathways between Normal Development and the Tumor Microenvironment. Cold Spring Harbor Perspectives in Medicine. 2026; 16(7).

Shahid, S; Mauguen, A; Mcavoy, D; Hosszu, K; Phillips, CL; Schultz, L; Hsieh, EM; Bonifant, CL; Fabrizio, VA; Bisogno, B; Pena, MP; Chapman, N; Boelens, J; Curran, KJ. Phase II One Arm Multicenter Study of Early Reinfusion of Tisagenlecleucel to Promote Durable B-cell Aplasia in Pediatric and Young Adult Patients with relapsed/refractory CD19-Positive B-cell Acute Lymphoblastic Leukemia (REFUEL) Transplantation and Cellular Therapy. 2026; 32(2):s593-s594.

Siegel, AH; Baldwin, A; Heisey, K; Herrera, K; Dufek, A; Patel, H; Kim, A; Bornhorst, M; Weiss, BD; Blank, PD; Fisher, MJ; Widemann, BC; Gross, AM. Long-Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1-Associated Plexiform Neurofibromas. Pediatric Blood and Cancer. 2026; 73(9):e70477.

Smiley, NP; Freese, C; Frankart, A; Breneman, J; Vatner, R; Takiar, V; Pater, L. ID #761 Feasibility study of hypofractionated radiotherapy in the setting of recurrent diffuse intrinsic pontine glioma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.320.

Smiley, NP; Lane, A; Webster, A; Blank, C; Hawkins, C; Hassall, T; Leach, J; Dorris, K; Jones, B; Hansford, JR; Zaghloul, M; Cheng, S; Hummel, TR; Hoffman, LM; Warren, KE. Re-irradiation practices and outcomes in patients with diffuse intrinsic pontine glioma (DIPG): A report from the International DIPG/DMG Registry. Neuro-Oncology Pediatrics. 2026; 2(2):wuag013.

Spurgeon, ME; Lange, TE; Baty, A; Li, H; Lambert, PF; Setchell, KDR; Wells, SI; Zhao, X. Lipid reprogramming of stratified squamous epithelium by the high-risk HPV E6 and E6/E7 oncoproteins. Metabolomics. 2026; 22(4).

Suarez, R; Roy, S; Knapke, S; Riddle, A; Raskin, S. ID #130 First Report of SHH-Activated Medulloblastoma in a Child With RRAS2-Related Noonan Syndrome. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.025.

Uible, EE; Choi, I; Clough, CA; Hassan, A; Anandappa, AJ; Fisher, J; Karki, B; Hueneman, K; Choi, K; Vick, EJ; Pasare, C; Cunningham, JT; Volk, AG; Starczynowski, DT. Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. Cell Chemical Biology. 2026; 33(1):59-73.e10.

Vacca, FS; Mochizuki, A; Patel, SK; Jones, B; Roy, S; Gupta, K. A frontal lobe mass in a 6-year-old girl. Brain Pathology. 2026; e70132.

Widemann, BC; Gross, AM; Dombi, E; Sankaran, H; Shern, JF. Evolution of Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Opportunities for Prevention and Therapeutic Strategies. Annual Review of Cancer Biology. 2026; 10(1):223-241.

Wright, E; Billups, C; Rush, S; Li, Y; Janns, A; Michalski, JM; Salloum, R; De Blank, P. Cumulative dose of chemotherapy and survival outcomes in children with average-risk medulloblastoma treated on Children's Oncology Group study ACNS0331. Neuro-Oncology. 2026; 28(7):1772-1780.

Wu, PV; O'brien, E; Verma, R; Vancauwenbergh, B; Sarangdhar, M; Jia, X; Song, D; Katta, A; Warnken, N; Sexton, C; Wunderlich, M; Perentesis, J. Abstract IA04: Identifying and targeting tumorigenic signals in the developing liver. Cancer Research. 2026; 86(18_Supplement_1):ia04-ia04.

Zarnegar-Lumley, S; Pommert, L; Lacayo, NJ; Petit, A; Shukla, N; Stevens, A; Gibson, A; Tarlock, K. Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2026.

Zhang, L; Eulo, V; Akshintala, S; Armstrong, AE; Gross, AM; Klesse, LJ; Lemberg, KM; Monga, V; Farouk Sait, S; Fisher, MJ; Widemann, BC; Pratilas, CA; Hirbe, AC; Kim, A. A Framework for Prioritizing Novel Agents in Malignant Peripheral Nerve Sheath Tumor Trials: A report from the Neurofibromatosis Clinical Trials Consortium. Neuro-Oncology. 2026.